Renovaro receives termination notice for License Agreement covering HIV candidate RENB-HV-01

Lunai Bioworks Inc.

Weird Science LLC terminated the License Agreement for RENB-HV-01 on March 1, 2024.
Renovaro had previously deprioritized RENB-HV-01 as costly and long-term, focusing on faster pipelines.
Lead candidate is now RENB-DC-11, a potential cancer vaccine for solid tumors; HIV programs continue under other licenses.
Company is evaluating all options regarding the termination and does not acknowledge the termination as effective.

item 1.02

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Lunai Bioworks Inc. terminated License Agreement with Weird Science LLC (effective 2024-03-01).

Action: termination
Agreement: license
Counterparty: Weird Science LLC
Effective: 2024-03-01

Exact text from the filing

On March 1, 2024, Renovaro Inc. (the “Company”) received a notice from the sole manager of Weird Science LLC terminating the License Agreement by and between Weird Science LLC and Enochian Biopharma, Inc. (now known as Renovaro Biosciences, Inc.), a wholly-owned subsidiary of the Company, dated February 16, 2018 (the “License Agreement”).

View on SEC.gov

632 material agreements filed in the last 30 days. Browse all material agreements →

Lunai Bioworks Inc. filing history →

Source: SEC EDGAR

accession 0001731122-24-000372

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.